Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polymyxin b sulfate + bacitracin zinc + neomycin is a **topical ophthalmic triple-antibiotic combination** used for the treatment of superficial bacterial infections of the external eye and its adnexa, including conjunctivitis, keratitis, keratoconjunctivitis, blepharitis, and blepharoconjunctivitis caused by susceptible organisms. The ointment combines three small-molecule antibiotics with complementary antibacterial spectra: polymyxin B disrupts the cell membrane of susceptible gram-negative bacteria, neomycin is an aminoglycoside that inhibits bacterial protein synthesis, and bacitracin inhibits bacterial cell wall synthesis with primary activity against gram-positive organisms. It has been marketed as ophthalmic ointment products including Neo-Polycin and Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, and the provided context identifies Bausch & Lomb as a developer/marketer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polymyxin b sulfate + bacitracin zinc + neomycin.